Introduction: Octreotide is a somatostatin analogue, which improves the management of neuroendocrine tumor (NET) patients. Octreotide acts through somatostatin receptors (SSTRs). However, the molecular mechanisms leading to successful therapy or curative effects are largely unknown, particularly when SSTRs levels are low or absent.
Aim(s): To provide novel insights into regulative octreotide pathways on human NET cells using CNDT2.5 as a novel in vitro model.
Materials and methods: CNDT2.5 cells were treated from one day up to 16 months with Octreotide and then were profiled using Affymetrix microarray analysis. QRT-PCR, western blot and immunohistochemistry analyses validated CNDT2.5 cells in silico data. In addition, small-intestine-NET tissue blocks at different stages of disease and laser-microdissected tumor cells analyses confirmed the findings.
Conference: 9th Annual ENETS Conference (2012)
Presenting Author: Su-Chen Li
To read results and conclusion, please login ...
Further abstracts you may be interested in